CESSATECH A/S DK -20 (8GN) - Total Assets
Based on the latest financial reports, CESSATECH A/S DK -20 (8GN) holds total assets worth €13.39 Million EUR (≈ $15.65 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CESSATECH A/S DK -20 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
CESSATECH A/S DK -20 - Total Assets Trend (2021–2025)
This chart illustrates how CESSATECH A/S DK -20's total assets have evolved over time, based on quarterly financial data. See 8GN total equity for net asset value and shareholders' equity analysis.
CESSATECH A/S DK -20 - Asset Composition Analysis
Current Asset Composition (December 2025)
CESSATECH A/S DK -20's total assets of €13.39 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 64.2% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €203.00K | 1.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CESSATECH A/S DK -20's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 8GN company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CESSATECH A/S DK -20's current assets represent 98.5% of total assets in 2025, a decrease from 99.3% in 2021.
- Cash Position: Cash and equivalents constituted 64.2% of total assets in 2025, up from 10.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 1.5% of total assets.
CESSATECH A/S DK -20 Competitors by Total Assets
Key competitors of CESSATECH A/S DK -20 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
CESSATECH A/S DK -20 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.69 | 2.06 | 4.23 |
| Quick Ratio | 10.69 | 2.06 | 4.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €11.95 Million | €8.07 Million | €14.89 Million |
CESSATECH A/S DK -20 - Advanced Valuation Insights
This section examines the relationship between CESSATECH A/S DK -20's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.75 |
| Latest Market Cap to Assets Ratio | 2.89 |
| Asset Growth Rate (YoY) | -15.8% |
| Total Assets | €13.39 Million |
| Market Capitalization | $38.64 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values CESSATECH A/S DK -20's assets at a significant premium (2.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: CESSATECH A/S DK -20's assets decreased by 15.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CESSATECH A/S DK -20 (2021–2025)
The table below shows the annual total assets of CESSATECH A/S DK -20 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €13.39 Million ≈ $15.65 Million |
-15.79% |
| 2024-12-31 | €15.90 Million ≈ $18.59 Million |
+86.97% |
| 2023-12-31 | €8.50 Million ≈ $9.94 Million |
-69.83% |
| 2022-12-31 | €28.19 Million ≈ $32.95 Million |
-8.04% |
| 2021-12-31 | €30.65 Million ≈ $35.84 Million |
-- |
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-c… Read more